Proteins and Peptides

20 Sep 2016 Synthetic Biologics Announces Completion of Enrollment for Phase 2b Proof-of-Concept Clinical Trial for SYN-004 (ribaxamase) for the Prevention of Clostridium Difficile Infection, Antibiotic-Associated Diarrhea and the Emergence of Antibiotic-Resistant Or
20 Sep 2016 BioLineRx Announces Initiation of Phase 2a Trial of BL-8040 in Combination With KEYTRUDA® (pembrolizumab) for Treatment of Pancreatic Cancer
20 Sep 2016 Bexion Pharmaceuticals Doses First Patient in Phase I Trial of BXQ-350 For Patients with Advanced Solid Tumors at the University of Cincinnati Cancer Institute
19 Sep 2016 Stealth BioTherapeutics Reports Elamipretide Improved Skeletal Muscle Bioenergetics in the Elderly
17 Sep 2016 Phase III Combination Trial of BYDUREON and FARXIGA Shows Significant Blood Sugar Reduction in Patients with Type 2 Diabetes
16 Sep 2016 Semaglutide reduced major cardiovascular events by 26% in adults with type 2 diabetes at high cardiovascular risk
15 Sep 2016 BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease
14 Sep 2016 Inotrem Successfully Completes Its First Phase I Clinical Trial with Motrem™, a TREM-1 Pathway Modulator for the Treatment of Septic Shock
13 Sep 2016 Sanofi's Fixed-Ratio Combination Helps More Patients Reach Mealtime Blood Sugar Target than Insulin Glargine Alone
13 Sep 2016 Semaglutide Demonstrated Superior HbA1c Reduction vs Placebo as Add-on to Basal Insulin Alone or with Metformin in Adults with type 2 Diabetes
13 Sep 2016 Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Primary Mitochondrial Disease
13 Sep 2016 Alizé Pharma III presents preclinical results from its I-HBD1 program at the Annual Meeting of the American Society for Bone and Mineral Research
09 Sep 2016 Emmaus Life Sciences Submits New Drug Application for Sickle Cell Disease Treatment
09 Sep 2016 Avelas Biosciences Completes Patient Enrollment for AVB-620 Phase 1b Clinical Trial
08 Sep 2016 La Jolla Pharmaceutical Company Reports Positive Results from Phase 1 Study of LJPC-401
07 Sep 2016 BioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease
01 Sep 2016 Long Acting Growth Hormone Based on Amunix' XTEN(R) Technology Completes Enrollment of Phase 3 Trial
31 Aug 2016 The Medicines Company Provides Update on Dyslipidemia Programs
30 Aug 2016 FDA Accepts CSL Behring's Biologics License Application for First Subcutaneous Prophylactic Therapy to Prevent Hereditary Angioedema Attacks
30 Aug 2016 Aeglea BioTherapeutics Doses First Patient in Phase 1 Trial of AEB1102 for the Treatment of Hematological Malignancies
29 Aug 2016 ERYTECH Completes Patient Enrollment in Phase 2b Trial for eryaspase (GRASPA®) in Acute Myeloid Leukemia
27 Aug 2016 Adocia Announces Topline Results of Indian Phase 3 Trial of BioChaperone PDGF for Diabetic Foot Ulcer
23 Aug 2016 Hansa Medical: Top line results from the Swedish ongoing Phase II study with IdeS in sensitized patients presented
22 Aug 2016 Versartis Announces Completion of Enrollment in Phase 3 VELOCITY Trial of Somavaratan in Pediatric GHD
21 Aug 2016 Sanofi Provides Update on New Drug Application for Investigational Once-Daily Fixed-Ratio Combination of Insulin Glargine and Lixisenatide

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top